Moreover, "in vitro" and preclinical models have shown that tumor gastric cells displaying MET gene amplification are "addicted" to the constitutive activity of this receptor for their growth and maintenance [8-10], thus suggesting that patients affected by this cancer could be ideal candidates for anti-MET targeted therapies. This evidence concerns the gene MET and neoplasm.